Listed

Insight Molecular Diagnostics Inc.

IMDXNasdaqCIK 1642380HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$239.0kRevenue, Q2 FY2026, three months to 2026-06-30$239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 10, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$239.0kRevenue, Q2 FY2026, three months to 2026-06-30$239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure−53.9% on a year earlier
  • Gross margin65.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $157.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure+0.4 pts on a year earlier
  • Operating margin−4770.7%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure−2870.7 pts on a year earlier
  • Net margin−4711.3%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$11.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure−2830.6 pts on a year earlier
  • Diluted EPS−$0.31Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure−3.3% on a year earlier
  • Free cash flow−$10.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Capital expenditure: $779.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Report this figure−54.0% on a year earlier

Last eight quarters

Full statements
Revenue$239.0kGross margin 65.7%
Diluted EPS−$0.31, Q2 FY2026
Free cash flow−$10.0m, Q2 FY2026
Insight Molecular Diagnostics Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.1Revenue, Q3 FY2024, three months to 2024-09-30$115.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure1.5Revenue, Q4 FY2024, three months to 2024-12-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure2.1Revenue, Q1 FY2025, three months to 2025-03-31$2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure0.5Revenue, Q2 FY2025, three months to 2025-06-30$518.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure0.3Revenue, Q3 FY2025, three months to 2025-09-30$260.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure1.1Revenue, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$32.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure0.2Revenue, Q2 FY2026, three months to 2026-06-30$239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure
Gross margin%43.5%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $50.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $115.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure40.0%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $595.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure62.0%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $1.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure65.3%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $338.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $518.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure53.5%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $139.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $260.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure43.5%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $496.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure46.9%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $15.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $32.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure65.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $157.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure
Operating margin%(11752.2%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $115.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure(2262.9%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$33.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(318.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(1900.0%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$9.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $518.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure(4249.2%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$11.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $260.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure(2057.5%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$23.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(13790.6%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $32.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(4770.7%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure
Net margin%(11733.0%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$13.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $115.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure(2255.1%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$33.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(312.0%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(1880.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $518.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure(4174.6%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$10.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Revenue: $260.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figure(2015.4%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(13406.3%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Revenue: $32.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(4711.3%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$11.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Revenue: $239.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure
Diluted EPS$ per share(0.98)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figurenot reported (Diluted EPS not reported)(0.26)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(0.30)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure(0.34)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274266.Report this figurenot reported (Diluted EPS not reported)(0.12)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(0.31)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001642380-26-000011.Report this figure
Free cash flow$m(5.6)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274266. Derived: 9-month figure less the 6-month figure.Capital expenditure: $87.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274266. Derived: 9-month figure less the 6-month figure.Report this figure(5.6)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(6.1)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Capital expenditure: $307.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(6.5)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Capital expenditure: $349.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Report this figure(5.7)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274266. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274266. Derived: 9-month figure less the 6-month figure.Report this figure(7.0)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001642380-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure(8.3)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Capital expenditure: $613.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001642380-26-000008.Report this figure(10.0)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Capital expenditure: $779.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001642380-26-000011. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$4.1mGross margin 56.7%
Diluted EPS−$1.65, FY2025
Free cash flow−$25.4m, FY2025
Insight Molecular Diagnostics Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m2.2Revenue, FY2021, twelve months to 2021-12-31$2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-04-12, accession 0001493152-23-012005.Report this figure1.0Revenue, FY2022, twelve months to 2022-12-31$958.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure1.5Revenue, FY2023, twelve months to 2023-12-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure1.9Revenue, FY2024, twelve months to 2024-12-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure4.1Revenue, FY2025, twelve months to 2025-12-31$4.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure
Gross margin%64.6%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $1.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-04-12, accession 0001493152-23-012005.Revenue: $2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-04-12, accession 0001493152-23-012005.Report this figure(1.9%)Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: −$18.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-04-16, accession 0001493152-24-014720.Revenue: $958.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure27.5%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $413.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-24, accession 0000950170-25-043852.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure39.3%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $740.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure56.7%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $2.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $4.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure
Operating margin%(2444.3%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$53.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-04-12, accession 0001493152-23-012005.Revenue: $2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-04-12, accession 0001493152-23-012005.Report this figure(1878.6%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$18.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-04-16, accession 0001493152-24-014720.Revenue: $958.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure(1672.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$25.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0000950170-25-043852.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure(3245.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$61.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure(1260.8%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$51.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $4.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure
Net margin%(2916.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$64.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-04-12, accession 0001493152-23-012005.Revenue: $2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-04-12, accession 0001493152-23-012005.Report this figure(7609.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$72.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-04-16, accession 0001493152-24-014720.Revenue: $958.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure(1848.4%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$27.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0000950170-25-043852.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure(3225.0%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$60.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure(1238.5%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$50.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001642380-26-000004.Revenue: $4.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure
Diluted EPS$ per share(0.72)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.72 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-11, accession 0001493152-22-006677.Report this figure(13.25)Diluted EPS, FY2022, twelve months to 2022-12-31−$13.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure(3.75)Diluted EPS, FY2023, twelve months to 2023-12-31−$3.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure(4.66)Diluted EPS, FY2024, twelve months to 2024-12-31−$4.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure(1.65)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure
Free cash flow$m(38.2)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$35.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-04-12, accession 0001493152-23-012005.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-04-12, accession 0001493152-23-012005.Report this figure(49.9)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$45.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-04-16, accession 0001493152-24-014720.Capital expenditure: $4.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-04-16, accession 0001493152-24-014720.Report this figure(23.6)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$23.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0000950170-25-043852.Capital expenditure: $281.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0000950170-25-043852.Report this figure(21.2)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001642380-26-000004.Capital expenditure: $516.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure(25.4)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001642380-26-000004.Capital expenditure: $3.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001642380-26-000004.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Insight Molecular Diagnostics Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BROADWOOD CAPITAL INC2026-06-30$74.8m12,684,884Added+753,045
AWM Investment Company, Inc.2026-06-30$16.7m2,836,692Added+30,436
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$4.3m735,847Added+198,686
PURA VIDA INVESTMENTS, LLC2026-06-30$2.9m484,845Reduced−462,289
Family Office Research LLC2026-06-30$2.2m368,849Added+241,583
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$1.5m256,903Reduced−5,150
JANE STREET GROUP, LLC2026-06-30$930.3k157,682New+157,682
BlackRock, Inc.2026-06-30$888.1k150,521Added+15,176
VANGUARD FIDUCIARY TRUST CO2026-06-30$735.0k124,576Reduced−8,015
STATE STREET CORP2026-06-30$543.5k92,124Added+41,370

Recent filings

All 670 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Insight Molecular Diagnostics Inc., recent filings
FiledFormWhat it isAccession number
2026-09-2116:05 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001493152-26-043560
2026-08-1016:14 ET10-QQuarterly reportPeriod 2026-06-300001642380-26-000011
2026-08-1016:10 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-036863
2026-06-1716:05 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001493152-26-029078
2026-05-1316:15 ET10-QQuarterly reportPeriod 2026-03-310001642380-26-000008
2026-05-1316:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001493152-26-022721
2026-05-1316:05 ET8-K/A8.01 Other events0001493152-26-022708
2026-04-3016:14 ETDEF 14AProxy statementPeriod 2026-04-300001493152-26-020502
2026-04-3016:07 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-020461
2026-04-2719:14 ETSCHEDULE 13D/AOwnership report, active investor, amended0000919574-26-002415

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1642380
Tickers
IMDX
Exchange
Nasdaq
SIC code
2835 In Vitro & In Vivo Diagnostic Substances
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
CA
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
OncoCyte Corp (to 2025-06-17); Oncocyte Corp (to 2025-06-17)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.